“`html
Improved Diagnosis and Treatment for Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations
Study Overview
- Reviewed 395 MDS patients at our center from 2018 to 2023
- Identified 39 patients with lower-risk MDS and SF3B1 mutations
- Supports the revised 2022 definitions of the World Health Organization (WHO) and International Consensus Classification (ICC)
Key Findings
- Lower-risk MDS-RS patients had reduced transfusion dependency with luspatercept treatment
- A quarter of patients would be missed using only the morphologic criterion of RS greater than 15%
- Supports the shift toward molecularly defined subtypes of MDS and appropriate testing
Source: Curr Oncol. 2024 Mar 29;31(4):1762-1773
“`
